Related Experiment Video
Updated: Jun 22, 2026

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011
1Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, UK.
Abstract:
The subject of this application is N(4)-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N(2)-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine xinafoate salt, as well as inhalant formulations of the salt and a process for the preparation of the salt. This salt is probably R-343, a Syk kinase inhibitor being developed under license by Pfizer, an inhaled formulation of which is in Phase I development for the treatment of asthma.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
05:45A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Related Concept Videos
Respiratory Syncytial Virus Disease
Inhalational Anesthetics: Overview
Inhaled Medications
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...